Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Enlivex (ENLV) Stock Price & Analysis
371 Followers
ENLV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $4.59
Previous Close$1.36
Volume62.86K
Average Volume (3M)74.18K
Market Cap
$28.28M
Enterprise Value$1.31M
Total Cash (Recent Filing)$27.32M
Total Debt (Recent Filing)$346.00K
Price to Earnings (P/E)―
Beta1.12
Next Earnings
May 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding18,598,555
10 Day Avg. Volume97,842
30 Day Avg. Volume74,181
Standard Deviation0.29
R-Squared0.05
Alpha-0.00804
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$6.00Price Target Upside337.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Enlivex News
PremiumCompany Announcements
Enlivex Commences Key Trial for Thumb Osteoarthritis
PremiumCompany Announcements
Enlivex Webinar to Discuss Breakthrough Immunotherapy
PremiumCompany Announcements
Enlivex’s Allocetra Shows Promise in Osteoarthritis Trial
PremiumCompany Announcements
Enlivex Therapeutics Reports Q1 FinancialsBulls Say, Bears Say
Bulls Say
Clinical DataSubstantial reductions in SOFA scores and a significant reduction in overall mortality rate were observed in Allocetra-treated patients.
Clinical TrialsIsraeli Ministry of Health authorized the initiation of an investigator-initiated, randomized, placebo-controlled Phase 1/2 trial to evaluate the efficacy, safety and tolerability of Allocetra for thumb osteoarthritis.
Regulatory ApprovalsThe Danish Medicines Agency (DKMA) authorized the expansion of the Phase 1/2 trial program into Denmark.
Bears Say
Clinical StudiesMid-stage sepsis trial yields mixed results, indicating uncertainty in the drug's effectiveness.
Drug ApprovalAnalyst lowers price target due to a reduced probability of drug approval in the sepsis indication.
Market PenetrationLower-than-expected market penetration poses a significant risk to the stock's performance.
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
<0.01% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.15 and its highest was $4.59 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Currently, no data Available
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 23, 2025 which is in 304 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 20,871,780 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went up 2.19%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Among the largest hedge funds holding Enlivex Therapeutics Ltd’s share is ARK Investment Management LLC. It holds Enlivex Therapeutics Ltd’s shares valued at N/A.
---
Enlivex Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (337.96% Upside)
$6.00 (337.96% Upside)
Hedge Fund Trend
Decreased
By 331.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.65%
12-Months-Change
Fundamentals
Return on Equity
-67.14%
Trailing 12-Months
Asset Growth
-48.27%
Trailing 12-Months
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
---
ENLV Stock 12 Month Forecast
Average Price Target
$6.00
▲(337.96% Upside)
Technical Analysis
Best Analysts Covering ENLV
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-28.59%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -28.59% per trade.
---